Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4792617
Max Phase: Preclinical
Molecular Formula: C38H41F3N3O5P
Molecular Weight: 707.73
Molecule Type: Unknown
Associated Items:
ID: ALA4792617
Max Phase: Preclinical
Molecular Formula: C38H41F3N3O5P
Molecular Weight: 707.73
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCOP(=O)(Cc1cccc(COc2ccccc2OC2CCN(Cc3ccc4nc(-c5cccc(C(F)(F)F)c5)[nH]c4c3)CC2)c1)OCC
Standard InChI: InChI=1S/C38H41F3N3O5P/c1-3-47-50(45,48-4-2)26-29-10-7-9-28(21-29)25-46-35-13-5-6-14-36(35)49-32-17-19-44(20-18-32)24-27-15-16-33-34(22-27)43-37(42-33)30-11-8-12-31(23-30)38(39,40)41/h5-16,21-23,32H,3-4,17-20,24-26H2,1-2H3,(H,42,43)
Standard InChI Key: YPONQFDDBHJAOJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 707.73 | Molecular Weight (Monoisotopic): 707.2736 | AlogP: 9.64 | #Rotatable Bonds: 14 |
Polar Surface Area: 85.91 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 1 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.38 | CX Basic pKa: 8.31 | CX LogP: 7.69 | CX LogD: 6.72 |
Aromatic Rings: 5 | Heavy Atoms: 50 | QED Weighted: 0.12 | Np Likeness Score: -0.93 |
1. Bessières M,Plebanek E,Chatterjee P,Shrivastava-Ranjan P,Flint M,Spiropoulou CF,Warszycki D,Bojarski AJ,Roy V,Agrofoglio LA. (2021) Design, synthesis and biological evaluation of 2-substituted-6-[(4-substituted-1-piperidyl)methyl]-1H-benzimidazoles as inhibitors of ebola virus infection., 214 [PMID:33548632] [10.1016/j.ejmech.2021.113211] |
Source(1):